Bahari Gholamreza, Hashemi Mohammad, Naderi Majid, Sadeghi-Bojd Simin, Taheri Mohsen
Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan 98167-43181, Iran.
Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan 98167-43181, Iran.
Biomed Rep. 2018 Feb;8(2):184-190. doi: 10.3892/br.2017.1028. Epub 2017 Dec 13.
The present case-control study was conducted on 110 children with acute lymphoblastic leukemia (ALL) and 120 healthy children to determine the impact of polymorphisms in paired-box gene 8 (PAX8) antisense RNA 1 (PAX8-AS1), namely rs4848320 C>T, rs6726151 T>G and rs1110839 G>T, on ALL risk. Genotyping was performed through the polymerase chain reaction-restriction fragment length polymorphism method. The findings indicated that the rs4848320 variant increased the risk of ALL in codominant [CT vs. CC: odds ratio (OR)=2.13, 95% confidence interval (CI)=1.16-3.90, P=0.014; and TT vs. CC: OR=2.21, 95% CI=1.03-4.74, P=0.041], dominant (CT+TT vs. CC: OR=2.15, 95% CI=1.22-3.81, P=0.009,) and allele (T vs. C: OR=1.55, 95% CI=1.07-2.25, P=0.024) inheritance models. The rs6726151 variant significantly increased the risk of ALL in codominant (GT vs. GG: OR=1.88, 95% CI=1.08-3.27, P=0.036) and overdominant (GT vs. GG+TT: OR=2.08, 95% CI=1.23-3.53, P=0.008) inheritance models. No significant relationship was identified between the rs1110839 G>T variant and disease risk/protection in childhood ALL. In conclusion, the findings of the present study indicated that rs4848320 and rs6726151 polymorphisms of PAX8-AS1 may be a risk factor for the development of childhood ALL. Further studies with larger sample sizes and different ethnicities are now required to confirm these findings.
本病例对照研究针对110例急性淋巴细胞白血病(ALL)患儿和120例健康儿童开展,以确定配对盒基因8(PAX8)反义RNA 1(PAX8-AS1)中的多态性,即rs4848320 C>T、rs6726151 T>G和rs1110839 G>T,对ALL风险的影响。通过聚合酶链反应-限制性片段长度多态性方法进行基因分型。研究结果表明,rs4848320变异在共显性[CT与CC:比值比(OR)=2.13,95%置信区间(CI)=1.16-3.90,P=0.014;TT与CC:OR=2.21,95% CI=1.03-4.74,P=0.041]、显性(CT+TT与CC:OR=2.